|
1
|
Narita K, Kikuchi T, Watanabe K, et al:
Total synthesis of the bicyclic depsipeptide HDAC inhibitors
spiruchostatins A and B, 5″-epi-spiruchostatin B, FK228 (FR901228)
and preliminary evaluation of their biological activity. Chemistry.
15:11174–11186. 2009.PubMed/NCBI
|
|
2
|
Ocker M and Schneider-Stock R: Histone
deacetylase inhibitors: signalling towards p21cip1/waf1. Int J
Biochem Cell Biol. 39:1367–1374. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xiong Y, Zhang H and Beach D: D type
cyclins associate with multiple protein kinases and the DNA
replication and repair factor PCNA. Cell. 71:505–514. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Han JW, Ahn SH, Kim YK, et al: Activation
of p21(WAF1/Cip1) transcription through Sp1 sites by histone
deacetylase inhibitor apicidin: involvement of protein kinase C. J
Biol Chem. 276:42084–42090. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fournel M, Trachy-Bourget MC, Yan PT, et
al: Sulfonamide anilides, a novel class of histone deacetylase
inhibitors, are anti-proliferative against human tumors. Cancer
Res. 62:4325–4330. 2002.
|
|
6
|
Archer SY, Meng S, Shei A and Hodin RA:
p21(WAF1) is required for butyrate-mediated growth inhibition of
human colon cancer cells. Proc Natl Acad Sci USA. 95:6791–6796.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sambucetti LC, Fischer DD, Zabludoff S, et
al: Histone deacetylase inhibition selectively alters the activity
and expression of cell cycle proteins leading to specific chromatin
acetylation and antiproliferative effects. J Biol Chem.
274:34940–34947. 1999. View Article : Google Scholar
|
|
8
|
Kanno SI, Maeda N, Tomizawa A, Yomogida S,
Katoh T and Ishikawa M: Involvement of p21waf1/cip1
expression in the cytotoxicity of the potent histone deacetylase
inhibitor spiruchostatin B towards susceptible NALM-6 human B cell
leukemia cells. Int J Oncol. 40:1391–1396. 2012.
|
|
9
|
Szakacs G, Annereau JP, Lababidi S, et al:
Predicting drug sensitivity and resistance: profiling ABC
transporter genes in cancer cells. Cancer Cell. 6:129–137. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xiao JJ, Huang Y, Dai Z, et al:
Chemoresistance to depsipeptide FK228
[(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone]
is mediated by reversible MDR1 induction in human cancer cell
lines. J Pharmacol Exp Ther. 314:467–475. 2005.PubMed/NCBI
|
|
11
|
Yamada H, Arakawa Y, Saito S, Agawa M,
Kano Y and Horiguchi-Yamada J: Depsipeptide-resistant KU812 cells
show reversible P-glycoprotein expression, hyper-acetylated
histones, and modulated gene expression profile. Leuk Res.
30:723–734. 2006. View Article : Google Scholar
|
|
12
|
Matsubara H, Watanabe M, Imai T, et al:
Involvement of extracellular signal-regulated kinase activation in
human osteosarcoma cell resistance to the histone deacetylase
inhibitor FK228
[(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dit
hia-5,8,20,23-tetraazabicyclo[8.7.6]
tricos-16-ene-3,6,9,19,22-pentone]. J Pharmacol Exp Ther.
328:839–848. 2009.PubMed/NCBI
|
|
13
|
Imesch P, Dedes KJ, Furlato M, Fink D and
Fedier A: MLH1 protects from resistance acquisition by the histone
deacetylase inhibitor trichostatin A in colon tumor cells. Int J
Oncol. 35:631–640. 2009.PubMed/NCBI
|
|
14
|
Dedes KJ, Dedes I, Imesch P, von Bueren
AO, Fink D and Fedier A: Acquired vorinostat resistance shows
partial cross-resistance to ‘second-generation’ HDAC inhibitors and
correlates with loss of histone acetylation and apoptosis but not
with altered HDAC and HAT activities. Anticancer Drugs. 20:321–333.
2009.PubMed/NCBI
|
|
15
|
Takizawa T, Watanabe K, Narita K, Oguchi
T, Abe H and Katoh T: Total synthesis of spiruchostatin B, a potent
histone deacetylase inhibitor, from a microorganism. Chem Commun
(Camb). 1677–1679. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kanno S, Kakuta M, Kitajima Y, et al:
Preventive effect of trimidox on oxidative stress in U937 cell
line. Biol Pharm Bull. 30:994–998. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kanno S, Hiura T, Ohtake T, et al:
Characterization of resistance to cytosine arabinoside (Ara-C) in
NALM-6 human B leukemia cells. Clin Chim Acta. 377:144–149. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kanno S, Higurashi A, Watanabe Y, Shouji
A, Asou K and Ishikawa M: Susceptibility to cytosine arabinoside
(Ara-C)-induced cytotoxicity in human leukemia cell lines. Toxicol
Lett. 152:149–158. 2004.PubMed/NCBI
|
|
19
|
Song JH, Choi CH, Yeom HJ, Hwang SY and
Kim TS: Monitoring the gene expression profiles of
doxorubicin-resistant acute myelocytic leukemia cells by DNA
microarray analysis. Life Sci. 79:193–202. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li W, Fan J, Banerjee D and Bertino JR:
Overexpression of p21(waf1) decreases G2-M arrest and apoptosis
induced by paclitaxel in human sarcoma cells lacking both p53 and
functional Rb protein. Mol Pharmacol. 55:1088–1093. 1999.PubMed/NCBI
|
|
21
|
Ahmed W, Rahmani M, Dent P and Grant S:
The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks
paclitaxel-induced G2M arrest and attenuates mitochondrial injury
and apoptosis in p53-null human leukemia cells. Cell Cycle.
3:1305–1311. 2004. View Article : Google Scholar
|
|
22
|
Fiskus W, Rao R, Fernandez P, et al:
Molecular and biologic characterization and drug sensitivity of
pan-histone deacetylase inhibitor-resistant acute myeloid leukemia
cells. Blood. 112:2896–2905. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bandyopadhyay D, Mishra A and Medrano EE:
Overexpression of histone deacetylase 1 confers resistance to
sodium butyrate-mediated apoptosis in melanoma cells through a
p53-mediated pathway. Cancer Res. 64:7706–7710. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Condorelli F, Gnemmi I, Vallario A,
Genazzani AA and Canonico PL: Inhibitors of histone deacetylase
(HDAC) restore the p53 pathway in neuroblastoma cells. Br J
Pharmacol. 153:657–668. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vrana JA, Decker RH, Johnson CR, et al:
Induction of apoptosis in U937 human leukemia cells by
suberoylanilide hydroxamic acid (SAHA) proceeds through pathways
that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but
independent of p53. Oncogene. 18:7016–7025. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Insinga A, Monestiroli S, Ronzoni S, et
al: Inhibitors of histone deacetylases induce tumor-selective
apoptosis through activation of the death receptor pathway. Nat
Med. 11:71–76. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sasakawa Y, Naoe Y, Inoue T, et al:
Effects of FK228, a novel histone deacetylase inhibitor, on tumor
growth and expression of p21 and c-myc genes in vivo. Cancer Lett.
195:161–168. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Peart MJ, Smyth GK, van Laar RK, et al:
Identification and functional significance of genes regulated by
structurally different histone deacetylase inhibitors. Proc Natl
Acad Sci USA. 102:3697–3702. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Imai T, Adachi S, Nishijo K, et al:
FR901228 induces tumor regression associated with induction of Fas
ligand and activation of Fas signaling in human osteosarcoma cells.
Oncogene. 22:9231–9242. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu S, Bishop WR and Liu M: Differential
effects of cell cycle regulatory protein p21(WAF1/Cip1) on
apoptosis and sensitivity to cancer chemotherapy. Drug Resist
Updat. 6:183–195. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Law JC, Ritke MK, Yalowich JC, Leder GH
and Ferrell RE: Mutational inactivation of the p53 gene in the
human erythroid leukemic K562 cell line. Leuk Res. 17:1045–1050.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Filippini G, Griffin S, Uhr M, et al: A
novel flow cytometric method for the quantification of p53 gene
expression. Cytometry. 31:180–186. 1998. View Article : Google Scholar : PubMed/NCBI
|
